No Data
PHARMARON (03759) received a portion of shares pledged and released by the actual controller, Lou Xiaoqiang, and Longtaikang.
PHARMARON (03759) announced that the company recently received a notification from one of its actual controllers, Mr. Lou Xiaoqiang, and his consensus...
PHARMARON (03759.HK) spent 7.2501 million Hong Kong dollars to repurchase 0.542 million shares on January 2.
Gelonghui, January 2丨PHARMARON (03759.HK) announced that on January 2, 2025, it spent 7.2501 million Hong Kong dollars to repurchase 0.542 million shares, with a repurchase price of 13.32-13.44 Hong Kong dollars per share.
Zhihui Tong Hong Kong Stock Repurchase Statistics | January 1.
Hong Kong Stock Repurchase Statistics | January 1
On December 30, PHARMARON (03759.HK) spent 6.1614 million HKD to repurchase 0.4405 million shares.
Gelonghui, December 30丨PHARMARON (03759.HK) announced that on December 30, 2024, it spent 6.1614 million Hong Kong dollars to repurchase 0.4405 million shares, with a repurchase price ranging from 13.94 to 14 Hong Kong dollars per share.
Minsheng Securities: Triple resonance moving upwards, focusing on pharmaceutical innovation and Consumer in 2025.
Looking ahead to 2025, there is a bullish outlook on the upward resonance of policy, fundamentals, and market sentiment, comprehensively optimistic about the pharmaceutical sector, with a focus on high-quality assets in pharmaceutical innovation and consumer sectors.
The Medical Care Sector is improving, with KJ Pharma (02171) rising over 18%. Institutions indicate that there is hope for entering a new growth cycle by 2025.
Jinwu Finance News | The Medical Care Sector is favorable, with the Hang Seng Healthcare Index rising 0.91% today, reporting 2338.61 points. Keji Pharmaceuticals (02171) rose over 18%, WUXI APPTEC (02359) rose 5.01%, Genting New Vision (01952) rose 4.02%, and PHARMARON (03759) rose 3.94%. Guosen Securities pointed out that domestic medical demand continues to upgrade, and the macro economy is expected to gradually improve. Currently, the Industry is undergoing considerable supply-side structural reforms, and centralized procurement for Pharmaceuticals and Medical Devices is nearing completion, with the potential to enter a new growth cycle in 2025. Geopolitical disturbances are affecting...
Expand
No Data
102884128 : getting disappointed with this counter. every day drop.